MedTrace Logo

Complications of UTI in Patients on Dapagliflozin

NCT02695173 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 683380

Last updated 2021-12-07

No results posted yet for this study

Summary

The objective of this study is to compare, by insulin use at the index date, the sex-specific incidence of hospitalization or emergency department (ED) visit for severe complications of urinary tract infections (UTI), defined as pyelonephritis and urosepsis, among patients with type 2 diabetes mellitus (T2DM) who are new users of dapagliflozin with those who are new users of antidiabetic drugs (ADs) in classes other than sodium-glucose cotransporter 2 (SGLT2) inhibitors, insulin monotherapy, metformin monotherapy, or sulfonylurea monotherapy.

Conditions

  • Severe Complications of Urinary Tract Infections

Sponsors & Collaborators

Principal Investigators

  • Catherine Johannes, Dr · RTI Health Solutions

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-01-01
Primary Completion
2020-09-01
Completion
2020-11-30

Countries

  • United States
  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02695173 on ClinicalTrials.gov